Conditions: Metastatic Pancreatic Cancer
Interventions: Diagnostic Test: Safety Laboratories; Other: AE Assessment; Other: Physical Exam; Other: Concomitant Medication Review; Diagnostic Test: Tumor Imaging; Drug: nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate; Drug: FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate; Drug: Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate
Sponsors: HonorHealth Research Institute; Cantex Pharmaceuticals
Terminated
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
